Empowered Funds’s Pacira BioSciences PCRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$6.57M Buy
262,102
+62,029
+31% +$1.57M 0.03% 634
2026
Q2
$5.08M Sell
200,073
-76,703
-28% -$1.81M 0.03% 702
2026
Q1
$6.26M Buy
+276,776
New +$6.15M 0.04% 554
2025
Q4
– Sell
-223,438
Closed -$5.76M – 1654
2025
Q3
$5.76M Sell
223,438
-15,535
-7% -$382K 0.06% 436
2025
Q2
$5.71M Buy
238,973
+4,744
+2% +$120K 0.06% 401
2025
Q1
$5.82M Buy
234,229
+4,744
+2% +$114K 0.08% 336
2024
Q4
$4.32M Buy
229,485
+11,149
+5% +$196K 0.06% 419
2024
Q3
$3.29M Buy
+218,336
New +$3.73M 0.05% 499

Other funds holding PCRX

Empowered Funds's PCRX Position: Q3 2026 in Review

Empowered Funds increased its Pacira BioSciences (PCRX) stake by 31% in Q3 2026, buying an estimated $1.57M and bringing the position to 262,102 shares worth $6.57M. The position accounts for 0.03% of the portfolio, ranked #634.

Empowered Funds first reported a position in PCRX in Q3 2024 and has held it in 8 quarters since. 258 funds tracked by Wall St. Rank hold PCRX as of Q3 2026.

  • Empowered Funds held 262,102 shares of Pacira BioSciences worth $6.57M as of Q3 2026.
  • Empowered Funds bought 62,029 Pacira BioSciences shares in Q3 2026, an estimated $1.57M.
  • Pacira BioSciences made up 0.03% of Empowered Funds's portfolio in Q3 2026, its #634 holding.
  • Empowered Funds first reported a position in Pacira BioSciences in Q3 2024 and has held it in 8 quarters since.
  • 258 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2026.

Based on Empowered Funds's 13F filing for Q3 2026, filed 13 Nov 2026.